Gencor shares topline results of body composition study

Gencor announced the topline results of its study on the body composition of overweight male and female subjects following supplementation with its Gynostemma pentaphyllum extract (ActivAMP).

Gencor (Irvine, CA) announced the topline results of its study on the body composition of overweight male and female subjects following supplementation with its Gynostemma pentaphyllum extract (ActivAMP). In the unpublished double-blind, randomized clinical trial, overweight subjects over the age of 18 were given either 450 mg of ActivAMP or placebo daily for 16 weeks. Results showed that male subjects experienced a significant reduction in visceral fat, and female subjects experienced a significant reduction in gynoid fat, compare to placebo.

“We are extremely pleased with our clinically meaningful study results on body composition,” said Chase Shyroc, vice president of sales & business development for Gencor, in a press release. “In previous human, animal and phytochemical studies, ActivAMP has achieved a demonstrated effect on the metabolic process via AMPk activation. This recent study provides additional validation for Gencor’s weight management platform.”

“Given the changes in both dietary and physical activity patterns of our society, we must continue to research methods of complementing lifestyle modifications, such as diet and exercise,” says Shyroc. “Gynostemma pentaphyllum has long been studied as a tool for management of healthy body composition because of its ability to reduce lipid and blood glucose levels.”